Search research articles
Contact Us
Filters
Showing results (71-80 of 100) with videos related to
Page
of 10
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 7, 2021
A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers
Adi Diab, Omid Hamid, John A Thompson, et al.
Research Square
|
July 3, 2023
Response to high dose ipilimumab plus temozolomide after progression on standard or low dose ipilimumab in advanced melanoma: a retrospective analysis
Julie Williamson, Muhammad Zaki Hidayatullah Fadlullah, Magdalena Kovacsovics-Bankowski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 23, 2019
Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non-Small Cell Lung Cancer
Siwen Hu-Lieskovan, Aaron Lisberg, Jesse M Zaretsky, et al.
Journal for Immunotherapy of Cancer
|
October 27, 2022
First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors
Omid Hamid, Alberto A Chiappori, John A Thompson, et al.
Current Oncology (Toronto, Ont.)
|
March 26, 2025
Dramatic Responses to High-Dose Ipilimumab Plus Temozolomide After Progression on Standard- or Low-Dose Ipilimumab in Advanced Melanoma
Julie Williamson, Muhammad Zaki Hidayatullah Fadlullah, Magdalena Kovacsovics-Bankowski, et al.
Cell Reports
|
May 13, 2017
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
Angel Garcia-Diaz, Daniel Sanghoon Shin, Blanca Homet Moreno, et al.
Journal for Immunotherapy of Cancer
|
January 17, 2024
Lower frequencies of circulating suppressive regulatory T cells and higher frequencies of CD4<sup>+</sup> naïve T cells at baseline are associated with severe immune-related adverse events in immune checkpoint inhibitor-treated melanoma
Magdalena Kovacsovics-Bankowski, Johanna M Sweere, Connor P Healy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 22, 2018
A Pilot Trial of the Combination of Transgenic NY-ESO-1-reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab
Theodore S Nowicki, Beata Berent-Maoz, Gardenia Cheung-Lau, et al.
Nature Communications
|
February 2, 2020
Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist
Giulia Parisi, Justin D Saco, Felix B Salazar, et al.
Cancer Discovery
|
May 30, 2020
Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade
Davis Y Torrejon, Gabriel Abril-Rodriguez, Ameya S Champhekar, et al.
Page
of 10
Search research articles
Search
Showing results (71-80 of 100) with videos related to
Sort By:
Page
of 10
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 7, 2021
A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers
Adi Diab, Omid Hamid, John A Thompson, et al.
Research Square
|
July 3, 2023
Response to high dose ipilimumab plus temozolomide after progression on standard or low dose ipilimumab in advanced melanoma: a retrospective analysis
Julie Williamson, Muhammad Zaki Hidayatullah Fadlullah, Magdalena Kovacsovics-Bankowski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 23, 2019
Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non-Small Cell Lung Cancer
Siwen Hu-Lieskovan, Aaron Lisberg, Jesse M Zaretsky, et al.
Journal for Immunotherapy of Cancer
|
October 27, 2022
First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors
Omid Hamid, Alberto A Chiappori, John A Thompson, et al.
Current Oncology (Toronto, Ont.)
|
March 26, 2025
Dramatic Responses to High-Dose Ipilimumab Plus Temozolomide After Progression on Standard- or Low-Dose Ipilimumab in Advanced Melanoma
Julie Williamson, Muhammad Zaki Hidayatullah Fadlullah, Magdalena Kovacsovics-Bankowski, et al.
Cell Reports
|
May 13, 2017
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
Angel Garcia-Diaz, Daniel Sanghoon Shin, Blanca Homet Moreno, et al.
Journal for Immunotherapy of Cancer
|
January 17, 2024
Lower frequencies of circulating suppressive regulatory T cells and higher frequencies of CD4<sup>+</sup> naïve T cells at baseline are associated with severe immune-related adverse events in immune checkpoint inhibitor-treated melanoma
Magdalena Kovacsovics-Bankowski, Johanna M Sweere, Connor P Healy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 22, 2018
A Pilot Trial of the Combination of Transgenic NY-ESO-1-reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab
Theodore S Nowicki, Beata Berent-Maoz, Gardenia Cheung-Lau, et al.
Nature Communications
|
February 2, 2020
Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist
Giulia Parisi, Justin D Saco, Felix B Salazar, et al.
Cancer Discovery
|
May 30, 2020
Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade
Davis Y Torrejon, Gabriel Abril-Rodriguez, Ameya S Champhekar, et al.
Page
of 10